explored the prognostic role of serum GGT in advanced urothelial carcinoma (aUC) patients.
INTRODUCTION AND OBJECTIVES:
To assess whether routine followup with computed tomography (CT) to detect asymptomatic visceral recurrence after radical cystectomy improves patient survival, we investigated the impact of symptoms at recurrence on patient survival.
METHODS: A total 348 radical cystectomy for muscle invasive bladder cancer (MIBC) were performed at our institution between January 1996 and December 2013. All patients had regular followup examinations with urine cytology every 3 months, blood biochemical test, and CT of the chest and abdomen every 6 months. We investigated the first site and date of tumor recurrence. Overall survival in patients with recurrence stratified by the mode of diagnosis (asymptomatic vs. symptomatic) was estimated using the Kaplan-Meier methods and compared with the log rank test. Cox proportional hazard regression models were used to evaluate the impact of the mode of diagnosing recurrence on survival.
RESULTS: A total 91 patients (20%) experienced recurrence after surgery. Seven patients (8%) were excluded due to missing data. Finally, 84 patients were enrolled in this retrospective study. Of those, 46 (55%) were asymptomatic and 38 (45%) were symptomatic. The most common recurrence site and symptom were lymph nodes (55%) and pain (53%). Overall survivals after surgery and recurrence to death were significantly longer in patients with asymptomatic recurrence compared with symptomatic recurrence. Multivariate analysis showed that a symptomatic recurrence is one of the independent risk factors for overall survival after surgery and recurrence.
CONCLUSIONS: Routine oncological followup for detection of asymptomatic recurrence may contribute better prognosis after radical cystectomy. CONCLUSIONS: Pure squamous cell and neuroendocrine carcinoma is associated with worse OS relative to UCB, whereas no difference was found between adenocarcinoma and UCB. All histological variants were associated with higher pT stage at surgery compared to UCB.
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MP34-20 CAN RADICAL CYSTECTOMY BE PERFORMED SAFELY IN THE METASTATIC SETTING? LOCATION OF METASTATIC BLADDER CANCER AS A DETERMINANT OF IN-HOSPITAL MORTALITY
Emanuele Zaffuto*, Marco Moschini, Milan, Italy; Sami-Ramzi LeyhBannurah, Hamburg, Germany; Stephanie Gazdovich, Montreal, Canada; Paolo Dell'Oglio, Milan, Italy; Raisa S. Pompe, Hamburg, Germany; Shahrokh F. Shariat, Vienna, Austria; Francesco Montorsi, Alberto Briganti, Milan, Italy; Fred Saad, Pierre I. Karakiewicz, Montreal, Canada INTRODUCTION AND OBJECTIVES: A recent study within a highly-select patient cohort suggested a survival benefit when local treatment is delivered in patients with metastatic bladder cancer (BCa). We relied on a similar patient cohort to examine in-hospital mortality (IHM) rates according to presence, absence and location of metastatic disease in BCa patients treated with radical cystectomy (RC).
METHODS: We identified 25,004 BCa patients treated with RC between 2004 and 2013 from the hospital claims data in the National Inpatients Sample database. Using International Classification of Diseases, 9th edition (ICD-9-CM) diagnostic codes, we identified 5,049 patients with metastatic disease. Metastatic BCa patients were stratified according to the presence of non-regional lymph node metastases (NRNM) in absence of distant organ involvement vs. presence of distant organ metastases (DM), regardless of nodal status. We tested postoperative IHM rates according to presence of metastases, as well as location of metastatic disease (NRNM vs. DM). Logistic regression analyses were adjusted for age, gender, race, comorbidities, length of hospitalization, hospital location, teaching status, hospital surgical volume and bed size.
RESULTS: Overall, 3,323 patients (13.3%) had NRNM, 1,726 (6.9%) had DM, and 19,965 (79.8%) had non-metastatic disease. Virtually all metastatic patients had a single metastatic site involvement (n¼4,458; 88.5%), while only a small proportion of individuals had metastatic involvement in 3 or more sites (n¼57; 1.1%). The most common metastatic sites were lymph nodes (76.0%; n¼3,830), other urinary organs (23.2%; n¼1,168), intestine (4.7%; n¼235) and retroperitoneum (4.1%; n¼209). Interestingly, bone and liver metastases represented only 1.6% (n¼81) and 1.1% (n¼55) of cases, respectively. IHM rates were 1.5% (n¼51), 3.5% (n¼60) and 2.0% (n¼404) for NRNM, DM and non-metastatic patients, respectively. The difference in IHM rates between DM and non-metastatic BCa patients was statistically significant (p<0.001). Conversely, NRNM patients did not exhibit different mortality rates than their counterparts without metastatic disease (p¼0.07). In multivariable logistic regression analyses, DM patients (OR: 1.68; 95% CI: 1.26-2.20; p<0.001), but not NRNM patients (OR: 0.84; 95% CI: 0.62-1.11; p¼0.2), were at increased risk of IHM.
CONCLUSIONS: DM patients are at an increased risk of IHM, compared to NRNM or non-metastatic patients. If at all indicated, RC in metastatic setting should be limited to patients with NRNM. 
PD21-01 DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE AFTER SURGERY: URETEROSCOPIC VERSUS SHOCK WAVE LITHOTRIPSY
Shuzo Hamamoto*, Teruaki Sugino, Rei Unno, Kazumi Taguchi, Ryosuke Ando, Nagoya, Japan; Shinsuke Okada, Chiba, Japan; Takaaki Inoue, Osaka, Japan; Atsushi Okada, Keiichi Tozawa, Takahiro Yasui, Nagoya, Japan
INTRODUCTION AND OBJECTIVES:
The aim of this study was to compare the longitudinal health-related quality of life (HRQoL) at 4 time points between patients undergoing ureteroscopic lithotripsy (URSL) and patients undergoing shock wave lithotripsy (SWL). We also aimed to evaluate the factors that significantly affect the HRQoL in patients with urolithiasis.
METHODS: We evaluated a total of 262 patients who underwent lithotripsy (SWL, n ¼ 61; URSL, n ¼ 201) for upper urinary tract calculi treatment between June 2012 and January 2015. All patients were administered the Short-Form 36-item survey (SF-36) to assess HRQoL at 4 time points: prior to surgery, on the day of discharge, and 1 and 6 months after lithotripsy. We evaluated stone-free rates, the occurrence of complications, and analgesic requirements in order to compare the effects of SWL versus URSL on HRQoL.
RESULTS: On the day of discharge, patients in the URSL group had significantly lower average scores on the SF-36 survey in 5 different domains (physical function, role physical, social functioning, role emotional, and mental health) and in 1 summary scale (role component score [RCS] ) than the SWL group. The stone-free rate at 3 months after lithotripsy was significantly lower in the SWL group than in the URSL group (72.1% vs. 93.0%; p < 0.001). Moreover, the analgesic
